INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us

Leveraging Technology in Phase I Clinical Trials

Ana Palijan, PhD

Ana Palijan, PhD

Director, Early Phase and Translational Research

Author picture

In the ever-evolving landscape of clinical research, Phase I studies are becoming increasingly complex. We’re proud to announce that two of our trailblazing colleagues, Ana Palijan, Director, Early Phase and Translational Research, and Éric Hardy, Senior Director, Biometrics, have contributed to a groundbreaking white paper that explores these complexities. Their expert analysis highlights the challenges and opportunities within Phase I trials, offering valuable insights for industry professionals.

Key Highlights:

  • In-depth Analysis: Explore the intricacies of Phase I studies, providing a comprehensive overview of the current landscape.
  • Expert Opinions: Gain insights from leading professionals who are at the forefront of clinical research.
  • Future Trends: Understand the emerging trends and how they might impact the future of Phase I trials.

This white paper is a must-read for anyone involved in clinical research. Whether you’re a seasoned professional or new to the field, the insights provided will enhance your understanding and approach to Phase I studies.

Dive into this white paper now!

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.
Talk to us

Jeff Smith

Chef de la direction
Linkedin

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≤3 days, and lowers costs, helping teams make informed go/no-go decisions faster.
LEARN MORE >